Our laboratory investigates signaling pathways that control apoptosis in esophageal cancer cells. In collaboration with clinical gastroenterologist and oncologist I have been working to find a novel and more effective therapeutic strategy for esophageal cancer.
We are interested in defining novel mechanisms regarding the transition to esophageal adenocarcinoma that could provide valuable insights for molecular diagnosis and to identify new targets for drug intervention. We develop and validate novel in vitro and in-vivo model which lead us to its use in future studies on esophageal adenocarcinoma pathogenesis, progression and for the screening of therapeutic drugs.
